<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 04 Jun 2021 22:25:37 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>读NEJM 涨知识 I Olaparib辅助治疗BRCA1或BRCA2突变乳腺癌</title><link>https://mp.weixin.qq.com/s/FFhcrCRmkb_4aFahuIvUzQ</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I Olaparib辅助治疗BRCA1或BRCA2突变乳腺癌]]></content:encoded><pubDate>Fri, 04 Jun 2021 19:28:09 +0800</pubDate></item><item><title>【2847】【2021 ASCO】名家解读：金玉其质，冰雪之心—乳腺癌的希望之鸽PALOMA-3总生存结果更新</title><link>https://mp.weixin.qq.com/s/Nf5vd0bbjDh2l2DAqqCBfQ</link><description></description><content:encoded><![CDATA[【2847】【2021 ASCO】名家解读：金玉其质，冰雪之心—乳腺癌的希望之鸽PALOMA-3总生存结果更新]]></content:encoded><pubDate>Fri, 04 Jun 2021 19:28:09 +0800</pubDate></item><item><title>读NEJM 涨知识 I Nivolumab辅助治疗非肌层浸润尿路上皮癌</title><link>https://mp.weixin.qq.com/s/4gCeTmlq0uutcQGiIdJiCA</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I Nivolumab辅助治疗非肌层浸润尿路上皮癌]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:34:25 +0800</pubDate></item><item><title>第四代EGFR抑制剂BLU-945开启1/2期临床研究</title><link>https://mp.weixin.qq.com/s/pZErtjFeKVYTuXPhogZEZA</link><description></description><content:encoded><![CDATA[第四代EGFR抑制剂BLU-945开启1/2期临床研究]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:34:25 +0800</pubDate></item><item><title>40岁以下肺癌患者的基因组学</title><link>https://mp.weixin.qq.com/s/4HPZACnz4uCnJbNDLCkvCA</link><description></description><content:encoded><![CDATA[40岁以下肺癌患者的基因组学]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:34:25 +0800</pubDate></item><item><title>ASCO I Brigatinib 日本一线治疗ALK阳性NSCLC患者结果</title><link>https://mp.weixin.qq.com/s/xL4HFmPF64zcMiUtKuISmA</link><description></description><content:encoded><![CDATA[ASCO I Brigatinib 日本一线治疗ALK阳性NSCLC患者结果]]></content:encoded><pubDate>Tue, 01 Jun 2021 23:03:29 +0800</pubDate></item><item><title>谷老师喊你戒烟啦</title><link>https://mp.weixin.qq.com/s/X30LDpc_nmyswIA_gD2wTw</link><description></description><content:encoded><![CDATA[谷老师喊你戒烟啦]]></content:encoded><pubDate>Tue, 01 Jun 2021 23:03:29 +0800</pubDate></item><item><title>Brigatinib治疗前序克唑替尼治疗后ROS1阳性NSCLC患者的II期研究：Barossa队列2结果。</title><link>https://mp.weixin.qq.com/s/uVVl62I6n4uX2MD5tPa6UQ</link><description></description><content:encoded><![CDATA[Brigatinib治疗前序克唑替尼治疗后ROS1阳性NSCLC患者的II期研究：Barossa队列2结果。]]></content:encoded><pubDate>Tue, 01 Jun 2021 22:18:24 +0800</pubDate></item><item><title>ASCO I 美国真实世界证据for NSCLC EGFR外显子20插入突变治疗模式和临床转归</title><link>https://mp.weixin.qq.com/s/2NRyk8OtGmpV-KH3QM6dtA</link><description></description><content:encoded><![CDATA[ASCO I 美国真实世界证据for NSCLC EGFR外显子20插入突变治疗模式和临床转归]]></content:encoded><pubDate>Mon, 31 May 2021 22:49:12 +0800</pubDate></item><item><title>【2844】【综述】头颈部鳞癌免疫治疗研究汇总：从晚期一线到新辅助治疗</title><link>https://mp.weixin.qq.com/s/6mT4RiPQtI-DY0QIe5WNXw</link><description></description><content:encoded><![CDATA[【2844】【综述】头颈部鳞癌免疫治疗研究汇总：从晚期一线到新辅助治疗]]></content:encoded><pubDate>Mon, 31 May 2021 22:49:12 +0800</pubDate></item><item><title>吴辉菁教授点评 | PTCL-NOS三线治疗使用维布妥昔单抗治疗病例分析</title><link>https://mp.weixin.qq.com/s/RkFgeAvhvNTxc1ZCkty8Lw</link><description></description><content:encoded><![CDATA[吴辉菁教授点评 | PTCL-NOS三线治疗使用维布妥昔单抗治疗病例分析]]></content:encoded><pubDate>Mon, 31 May 2021 22:49:12 +0800</pubDate></item><item><title>ASCO I Mobocertinib 含铂化疗后1/2期研究与EXCLAIM队列的更新结果</title><link>https://mp.weixin.qq.com/s/wXUaS5_nw3Km3RKd_OnZzQ</link><description></description><content:encoded><![CDATA[ASCO I Mobocertinib 含铂化疗后1/2期研究与EXCLAIM队列的更新结果]]></content:encoded><pubDate>Sun, 30 May 2021 18:42:05 +0800</pubDate></item><item><title>KRAS G12C抑制剂Sotorasib（AMG510）中文说明书</title><link>https://mp.weixin.qq.com/s/rPfkI_LgzvLqBVCBnDz_gQ</link><description></description><content:encoded><![CDATA[KRAS G12C抑制剂Sotorasib（AMG510）中文说明书]]></content:encoded><pubDate>Sun, 30 May 2021 18:42:05 +0800</pubDate></item><item><title>自发性细菌性腹膜炎！人血白蛋白请了解一下</title><link>https://mp.weixin.qq.com/s/MKfKhY7-if2ScYOSVYePvg</link><description></description><content:encoded><![CDATA[自发性细菌性腹膜炎！人血白蛋白请了解一下]]></content:encoded><pubDate>Sat, 29 May 2021 22:27:37 +0800</pubDate></item><item><title>【研究速递】水果和蔬菜的摄入与乳腺癌发病率：一项前瞻性研究的系统回顾和荟萃分析</title><link>https://mp.weixin.qq.com/s/GE08Exq9AwIPHpdm72QIKw</link><description></description><content:encoded><![CDATA[【研究速递】水果和蔬菜的摄入与乳腺癌发病率：一项前瞻性研究的系统回顾和荟萃分析]]></content:encoded><pubDate>Sat, 29 May 2021 22:27:37 +0800</pubDate></item><item><title>2021EHA大咖谈 | 胡凯教授：CAR-T治疗R/R DLBCL的分子遗传学背景及疗效</title><link>https://mp.weixin.qq.com/s/rrsO3kxXLhtGfK7axUWI2Q</link><description></description><content:encoded><![CDATA[2021EHA大咖谈 | 胡凯教授：CAR-T治疗R/R DLBCL的分子遗传学背景及疗效]]></content:encoded><pubDate>Sat, 29 May 2021 22:27:37 +0800</pubDate></item><item><title>武田制药发布2020财年全年财报：业绩保持稳健，利润率与现金流表现出色</title><link>https://mp.weixin.qq.com/s/jTYdvA4TbCphFUU4vwDGCA</link><description></description><content:encoded><![CDATA[武田制药发布2020财年全年财报：业绩保持稳健，利润率与现金流表现出色]]></content:encoded><pubDate>Fri, 28 May 2021 22:55:11 +0800</pubDate></item><item><title>【2021ASCO中国之声】剧透！梁爱斌教授解读2021ASCO两项中国CAR-T研究</title><link>https://mp.weixin.qq.com/s/AYk0kgFUazkO24njaNU-Ug</link><description></description><content:encoded><![CDATA[【2021ASCO中国之声】剧透！梁爱斌教授解读2021ASCO两项中国CAR-T研究]]></content:encoded><pubDate>Fri, 28 May 2021 22:55:11 +0800</pubDate></item><item><title>免疫单药或联合化疗治疗ROS1阳性NSCLC</title><link>https://mp.weixin.qq.com/s/gUpM0I97IZ-Wu1UYkgEFsA</link><description></description><content:encoded><![CDATA[免疫单药或联合化疗治疗ROS1阳性NSCLC]]></content:encoded><pubDate>Thu, 27 May 2021 21:40:38 +0800</pubDate></item><item><title>【2021ASCO】ZUMA-3研究的Ⅱ期结果：KTE-X19在R/R B-ALL成人患者显示出卓越的疗效</title><link>https://mp.weixin.qq.com/s/2mq5QJYPZ38OXDhdAlVv5A</link><description></description><content:encoded><![CDATA[【2021ASCO】ZUMA-3研究的Ⅱ期结果：KTE-X19在R/R B-ALL成人患者显示出卓越的疗效]]></content:encoded><pubDate>Thu, 27 May 2021 21:40:38 +0800</pubDate></item></channel></rss>